Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
about
Risperidone (depot) for schizophreniaSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsEffectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Almost all antipsychotics result in weight gain: a meta-analysis.Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonAdverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia.Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.Progress in compliance research and intervention: a commentary.Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Explicit review of risperidone long-acting injection prescribing practice.Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals.Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
P2860
Q24185901-CB941FD5-4A45-4364-B0A8-DFDFFF01D5BBQ26752965-394F7F7A-2D68-48B6-AC50-4B4F9B37B688Q28085407-896D951D-823C-4E79-ABD5-3C26F565E767Q30542486-57D96918-6148-46C7-B9B9-1B72A477F482Q34315836-23F640E0-4349-4198-99D5-3449C1B081B6Q34661499-E3B1B95F-C89F-4F1A-B7DF-2449E413B52DQ34720828-FE08AB46-2038-4BB4-B3A1-CCFD0631BD8EQ34775426-313A043E-0E52-4893-910B-8B8558BC9DEDQ35971060-075698B0-613E-48E3-8350-17E7B1645274Q36873892-BE95712B-8BDD-4F52-9BAD-43F434B48324Q37236148-E9CC8A5F-AF11-43BD-B5EF-8560775DF5D5Q37236153-13AB5C6F-830D-430D-8E5D-3A761653FB50Q37341552-84075C69-F1F7-43FF-A007-DB601047EF05Q37425054-5874E357-DF9B-4F71-82AD-9D98BAC5488AQ37451403-FB7787AE-1005-466A-BCA1-621EA16EE74FQ37778398-11CA397D-3FED-464B-AD67-41ADA566D4DCQ37948911-68057114-2118-46F9-A22D-6A9B89F5A2DBQ38010780-BB682CE9-16A0-4013-A0EF-31A215B03DC1Q38064842-B167A173-3E98-4A9D-84E3-C047664E40CEQ38086645-AB8D8F9F-7385-41D9-BAB0-2ABC5120801FQ38115487-EA7FCFEC-DD1A-45C2-BDA0-49C35D0A120BQ38206231-83D25AB7-36FA-49A9-9603-FCC5CA2A80C4Q41656775-ED271328-5D2F-4750-AC20-77ED2068C9B4Q44733793-F1C9DD4D-46F4-401B-8FD8-4D539958FC9CQ47733836-1091C373-8903-4064-8F44-E990247C7B31Q48201230-42C185F1-EA7E-450D-BA01-9F5C2438DF72Q48350364-A858AB21-B21E-40B4-8132-16A73453A5EEQ58760344-D5D17AA3-507D-4937-93D0-E9572C4A0DED
P2860
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Long-acting injectable risperi ...... controlled, open-label study.
@en
Long-acting injectable risperi ...... controlled, open-label study.
@nl
type
label
Long-acting injectable risperi ...... controlled, open-label study.
@en
Long-acting injectable risperi ...... controlled, open-label study.
@nl
prefLabel
Long-acting injectable risperi ...... controlled, open-label study.
@en
Long-acting injectable risperi ...... controlled, open-label study.
@nl
P2093
P1476
Long-acting injectable risperi ...... controlled, open-label study.
@en
P2093
Akbar Khan
Keith Karcher
Michael Ingham
Nicholas A Keks
P304
P356
10.1192/BJP.BP.105.017020
P407
P577
2007-08-01T00:00:00Z